SeekIn Receives CE Mark Approval for SeekInCare^® Pan Cancer Early Detection Test

This First-of-its-Kind Blood-based Pan Cancer Early Detection Test Combines Protein Markers, Genomic and Epigenetic Features of Cancer in Blood

SHENZHEN, China, Feb. 24, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for SeekInCare^® Cancer Detection Kit and is now ready to launch this test in European markets.

https://www.prnewswire.com/news-releases/seekin-receives-ce-mark-approval-for-seekincare-pan-cancer-early-detection-test-301489705.html?tc=eml_cleartime

SeekIn Receives CE Mark Approval for SeekInCare® Pan Cancer Early Detection Test

This First-of-its-Kind Blood-based Pan Cancer Early Detection Test Combines Protein Markers, Genomic and Epigenetic Features of Cancer in Blood

SeekIn Receives CE Mark Approval for SeekInCare^® Pan Cancer Early Detection Test